Baseline characteristics
| . | Elective cessation in remission (STOP) . | Continuous therapy (CONT) . | P . |
|---|---|---|---|
| N | 13 | 16 | |
| Age at AML diagnosis, | 74 | 72.5 | .92 |
| median years (range) | (65-80) | (66-80) | |
| Male (%) | 7 (54) | 9 (56) | .99 |
| Female (%) | 6 (46) | 7 (43) | |
| Cytogenetic risk (MRC2010) | |||
| Intermediate (%) | 12 (92) | 11 (69) | .29 |
| Adverse (%) | 1 (8) | 4 (25) | |
| Failed (%) | — | 1 (6) | |
| ELN2017 Classification | |||
| Favorable (%) | 5 (38) | 7 (43) | .95 |
| Intermediate (%) | 2 (16) | 2 (14) | |
| Adverse (%) | 6 (46) | 7 (43) | |
| Secondary AML (%) | 1 (8) | 4 (25) | .62 |
| Prior HMA (%) | — | 1 (6) | |
| Baseline molecular mutations | |||
| NPM1 (%) | 5 (38) | 7 (43) | — |
| IDH2 (%) | 5 (38) | 4 (25) | |
| IDH1 (%) | 2 (16) | 3 (21) | |
| FLT3-ITD (%) | 1 (8) | — | |
| TP53 (%) | — | 1 (7) | |
| Treatment received | |||
| VEN LDC (%) | 7 (50) | 2 (14) | .008 |
| VEN decitabine (%) | 6 (43) | 7 (43) | |
| VEN azacitidine (%) | — | 7 (43) | |
| Median no. of cycles received | 17 | 28 | .03 |
| (range) | (12-29) | (12-64) | |
| Median months on therapy | 19.3 | 28.8 | .01 |
| (range) | (14.4-35.8) | (14.0-61.3) | |
| Best response achieved | |||
| CR (%) | 12 (92) | 13 (81) | .86 |
| CRi/CRp (%) | 1 (8) | 3 (19) | |
| . | Elective cessation in remission (STOP) . | Continuous therapy (CONT) . | P . |
|---|---|---|---|
| N | 13 | 16 | |
| Age at AML diagnosis, | 74 | 72.5 | .92 |
| median years (range) | (65-80) | (66-80) | |
| Male (%) | 7 (54) | 9 (56) | .99 |
| Female (%) | 6 (46) | 7 (43) | |
| Cytogenetic risk (MRC2010) | |||
| Intermediate (%) | 12 (92) | 11 (69) | .29 |
| Adverse (%) | 1 (8) | 4 (25) | |
| Failed (%) | — | 1 (6) | |
| ELN2017 Classification | |||
| Favorable (%) | 5 (38) | 7 (43) | .95 |
| Intermediate (%) | 2 (16) | 2 (14) | |
| Adverse (%) | 6 (46) | 7 (43) | |
| Secondary AML (%) | 1 (8) | 4 (25) | .62 |
| Prior HMA (%) | — | 1 (6) | |
| Baseline molecular mutations | |||
| NPM1 (%) | 5 (38) | 7 (43) | — |
| IDH2 (%) | 5 (38) | 4 (25) | |
| IDH1 (%) | 2 (16) | 3 (21) | |
| FLT3-ITD (%) | 1 (8) | — | |
| TP53 (%) | — | 1 (7) | |
| Treatment received | |||
| VEN LDC (%) | 7 (50) | 2 (14) | .008 |
| VEN decitabine (%) | 6 (43) | 7 (43) | |
| VEN azacitidine (%) | — | 7 (43) | |
| Median no. of cycles received | 17 | 28 | .03 |
| (range) | (12-29) | (12-64) | |
| Median months on therapy | 19.3 | 28.8 | .01 |
| (range) | (14.4-35.8) | (14.0-61.3) | |
| Best response achieved | |||
| CR (%) | 12 (92) | 13 (81) | .86 |
| CRi/CRp (%) | 1 (8) | 3 (19) | |
CRi, complete remission with incomplete count recovery; CRp, complete remission with incomplete platelet recovery; ELN, European LeukemiaNet; MRC, Medical Research Council.